A Randomized, <scp>Placebo‐Controlled</scp> Phase <scp>III</scp> Extension Trial of the <scp>Long‐Term</scp> Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus-Reference-Cited by-同舟云学术

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

Published:2022-11-11 Issue:2 Volume:75 Page:253-265
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Kalunian Kenneth C.¹,Furie Richard²^ORCID,Morand Eric F.³^ORCID,Bruce Ian N.⁴,Manzi Susan⁵,Tanaka Yoshiya⁶^ORCID,Winthrop Kevin⁷^ORCID,Hupka Ihor⁸,Zhang Lijin (Jinny)⁹,Werther Shanti¹⁰,Abreu Gabriel¹¹,Hultquist Micki¹²,Tummala Raj¹²,Lindholm Catharina¹³,Al‐Mossawi Hussein¹⁴

Affiliation:

1. Division of Rheumatology, Allergy and Immunology University of California San Diego School of Medicine La Jolla California

2. Division of Rheumatology Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Great Neck New York

3. School of Clinical Sciences Monash University Melbourne Victoria Australia

4. Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, and Manchester Academic Health Science Centre Manchester UK

5. Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network Pittsburgh Pennsylvania

6. The First Department of Internal Medicine University of Occupational and Environmental Health, Japan Kitakyushu Japan

7. School of Public Health at Oregon Health and Science University Portland Oregon

8. Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca Warsaw Poland

9. Global Patient Safety, BioPharmaceuticals R&D, AstraZeneca Gaithersburg Maryland

10. Global Patient Safety, Biopharmaceuticals R&D, AstraZeneca Gothenburg Sweden

11. Biometrics, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden

12. Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca Gaithersburg Maryland

13. Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca Gothenburg Sweden

14. Clinical Development, Late Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca Cambridge UK

Funder

AstraZeneca

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.42392

Reference38 articles.

1. Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea

2. Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years

3. Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus

4. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biologics in Systemic Lupus Erythematosus: Recent Evolutions and Benefits;Pharmaceutics;2024-09-06

2. The Potential Use of Arsenic Trioxide in the Treatment of Systemic Lupus Erythematosus;International Journal of Molecular Sciences;2024-09-04

3. Innovations in Cutaneous Lupus;Dermatologic Clinics;2024-09

4. Interferonopathies: From concept to clinical practice;Best Practice & Research Clinical Rheumatology;2024-08

5. Neurological Impact of Type I Interferon Dysregulation;Rare Neurodegenerative Disorders - New Insights [Working Title];2024-07-31